These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3148149)

  • 21. The Nithsdale Schizophrenia survey: II. Abnormal movements.
    McCreadie RG; Barron ET; Winslow GS
    Br J Psychiatry; 1982 Jun; 140():587-90. PubMed ID: 6125227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexamethasone suppression test, schizophrenia and movement disorder.
    Aleem A; Kulkarni A; Yeragani VK
    Acta Psychiatr Scand; 1988 Dec; 78(6):689-94. PubMed ID: 3223326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia.
    An HM; Tan YL; Shi J; Wang ZR; Soars JC; Wu JQ; Yang FD; Huang XF; Zhang XY
    Schizophr Res; 2015 Mar; 162(1-3):261-8. PubMed ID: 25600548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolactin response in tardive dyskinesia.
    Wolf ME; Bowie L; Keener S; Mosnaim AD
    Biol Psychiatry; 1982 Apr; 17(4):485-90. PubMed ID: 7082714
    [No Abstract]   [Full Text] [Related]  

  • 26. Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia.
    Mosnaim AD; Wolf ME
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):27S-30S. PubMed ID: 2906066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of abnormal involuntary movements among chronic schizophrenics.
    Guy W; Ban TA; Wilson WH
    Int Clin Psychopharmacol; 1986 Apr; 1(2):134-44. PubMed ID: 3571941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High plasma clozapine levels in tardive dyskinesia.
    Pollack S; Lieberman J; Kleiner D; Szymanski S; Kane J; Borenstein M; Cooper T
    Psychopharmacol Bull; 1993; 29(2):257-62. PubMed ID: 8290674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone response to sodium valproate in chronic schizophrenia.
    Monteleone P; Maj M; Iovino M; Steardo L
    Biol Psychiatry; 1986 Jun; 21(7):588-94. PubMed ID: 3085738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia.
    Wu JQ; Chen DC; Tan YL; Soares JC; Zhang XY
    Hum Psychopharmacol; 2015 Jan; 30(1):57-63. PubMed ID: 25572310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V
    Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia.
    Monteleone P; Zontini G; Steardo L
    Psychoneuroendocrinology; 1985; 10(4):475-80. PubMed ID: 3003777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia.
    Widerlöv E; Häggström JE; Kilts CD; Andersson U; Breese GR; Mailman RB
    Acta Psychiatr Scand; 1982 Oct; 66(4):294-305. PubMed ID: 7148482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
    Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
    Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.
    Wu Q; Yuan F; Zhang S; Liu W; Miao Q; Zheng X; Lu S; Hou K
    Dis Markers; 2022; 2022():1767989. PubMed ID: 35299866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
    Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Antonozzi I; Frajese G
    Neuropsychobiology; 1990; 23(1):15-7. PubMed ID: 2280826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study.
    Bai YM; Chou KH; Lin CP; Chen IY; Li CT; Yang KC; Chou YH; Su TP
    Schizophr Res; 2009 Apr; 109(1-3):167-81. PubMed ID: 19261444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noradrenergic function in schizophrenia.
    Glazer WM; Charney DS; Heninger GR
    Arch Gen Psychiatry; 1987 Oct; 44(10):898-904. PubMed ID: 3662745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of sodium valproate on tardive dyskinesia--revisited.
    Fisk GG; York SM
    Br J Psychiatry; 1987 Apr; 150():542-6. PubMed ID: 3117156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.